Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0PWAOJ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SGN-CD228A
|
|||||
| Synonyms |
Anti-CD228-MMAE; SGN CD228A; SGN-CD228A; anti-CD228 antibody-drug conjugate
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Phase 1 (Terminated)
|
|||||
| Indication |
In total 6 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
hL49
|
Antibody Info | ||||
| Antigen Name |
Melanotransferrin (MELTF)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
b-glucuronidase cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| DrugMap ID | ||||||
| TTD ID | ||||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
| Standard Type | NCT Number | Clinical Status | Clinical Trial Description |
|---|---|---|---|
| Undisclosed | NCT04042480 |
Phase 1
|
A phase 1 study of SGN-CD228A in select advanced solid tumors.
|
Discovered Using Patient-derived Xenograft Model
| Standard Type | Value | Units | Animal Model (No. of PDX) |
|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
75
|
%
|
NSCLC PDX model
|
| Tumor Growth Inhibition value (TGI) |
100
|
%
|
NSCLC PDX model
|
Discovered Using Cell Line-derived Xenograft Model
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04042480 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 study of SGN-CD228A in select advanced solid tumors. | ||||
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 75.00% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 3.00 mg/kg.
|
||||
| In Vivo Model | NSCLC PDX model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 100.00% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | NSCLC PDX model | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 50.00% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Melanoma CDX model | ||||
| In Vitro Model | Cutaneous melanoma | SK-MEL-5 cells | CVCL_0527 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 62.50% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Melanoma CDX model | ||||
| In Vitro Model | Cutaneous melanoma | COLO 853 cells | CVCL_2003 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 100.00% | Positive CD228 expression (CD228+++/++) | ||
| Method Description |
SGN-CD228A was evaluated for antitumor activity in melanoma and NSCLC xenograft and PDX models.SGN-CD228A was administered at a single dose of 1.00 mg/kg.
|
||||
| In Vivo Model | Squamous NSCLC CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | Calu-1 cells | CVCL_0608 | ||
References